Eli Lilly Q3 Revenue of $24.4B Beats Expectations by Wide Margin, Full-Year Sales Guidance Raised to $91-92B
nashnova research
Eli Lilly posted Q3 revenue of $24.4 billion, topping Wall Street estimates by nearly $1.8 billion, and lifted full-year guidance to $91–$92 billion — the obesity and diabetes engines are still accelerating, not plateauing.
How big was the beat?
Adjusted EPS came in at $7.48, roughly 20% above the Street consensus of $6.26.
Revenue hit $24.4 billion versus the $22.61 billion analysts expected — a gap of nearly $1.8 billion.
This means → the market's growth model for Lilly is still too conservative; actual demand is outrunning even the most bullish consensus.
Why did Lilly raise full-year guidance?
Full-year revenue guidance jumped from $85–$87 billion to $91–$92 billion, a midpoint increase of roughly $5.5 billion.
Full-year adjusted EPS guidance, however, edged down to $35–$36 (from $35.50–$36.50) due to a $4.57-per-share one-time charge tied to an in-quarter acquisition.
In plain terms = Lilly is more confident about how much it can sell, but the cost of buying another company ate into profits — so the "how much we earn" number didn't rise alongside the "how much we sell" number.
Mounjaro and Zepbound — which drove the beat?
Mounjaro — a diabetes drug (tirzepatide, an injection that activates both the GIP and GLP-1 receptors) — posted global revenue of $10.72 billion, up 65% year-over-year. International sales surged 93%, the quarter's standout metric.
Zepbound, the obesity drug, generated $5.35 billion in Q3 revenue, up 49%, with the vast majority from the U.S. market.
This means → Mounjaro's growth story is shifting from "U.S.-carried" to "international acceleration," while Zepbound remains heavily U.S.-dependent — the two drugs' growth trajectories are diverging.
Volume up, price down — what does that mean?
U.S.: prescription volume rose 41%, but realized price fell 7%; total U.S. revenue still grew 34% to $15.1 billion.
International: volume jumped 76%, but realized price dropped 29%; revenue grew 47% to $9.3 billion.
Part of the price decline traces to last year's drug-pricing deal with the Trump administration; separately, U.S. Medicare began covering GLP-1 obesity indications in July through a temporary pilot program.
In plain terms = Lilly is trading lower prices for broader reach — once Medicare covers obesity drugs, the payer shifts from the patient's pocket to government insurance, and the addressable population expands sharply.
Oral drug Foundayo — weak spot or early innings?
Foundayo — an oral GLP-1 obesity pill (no injection needed) approved in April — posted Q3 sales of $184 million, below the Street estimate of roughly $229 million.
This is only its second full quarter on the market, competing head-to-head with Novo Nordisk's oral rival launched in January.
This reflects an oral GLP-1 market still in its earliest stage; whether Foundayo can ramp faster is the key variable to watch next quarter.
M&A — where is Lilly spending the cash?
Lilly announced the acquisition of Merida Biosciences during the quarter, targeting novel therapies for severe autoimmune and allergic diseases.
The deal's $4.57-per-share one-time charge is the direct reason full-year EPS guidance ticked lower.
This means → Lilly is converting GLP-1 profits into pipeline expansion — obesity-drug cash flow is funding the next generation of products.
市场有风险，内容仅供研究参考，不构成投资建议。